Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis
A legfontosabb adatok
- Ki végzi
- Chunshui He
- Hol
- Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou, Wuhan és Xiamen (Kína)Mind a 10 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2027. jan. 1.
- Várható befejezés
- 2030. dec. 31.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Drug-Coated Balloon-First Strategy
- Eluvia Drug-Eluting Stent-First Strategy
- A regiszteradat frissítve
- 2026. november 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults whose leg artery stent (in the thigh or behind the knee) has narrowed again and causes symptoms. The doctor chooses either a drug-coated balloon or an Eluvia drug-releasing stent as part of usual care.
- Életkor
- Older than 18 years (minimum age 18 Years).
- Nem
- All sexes can join.
- A betegség stádiuma
- Rutherford category 2-5 symptoms. A narrowing of 50% or more, or a full blockage, inside a stent in the superficial femoral or upper popliteal artery, placed more than 30 days before. The narrowing is inside the old stent or reaches no more than 3 cm (1,2 in) beyond it. Total length 30 cm (12 in) or less. At least one open artery below the knee. After the lesion is prepared, both treatments must still be possible.
- Korábbi kezelés
- People must already have a stent in the superficial femoral or upper popliteal artery, placed more than 30 days before.
A részvétel fő kizáró okai
- Pregnancy or breastfeeding.
- Rutherford category 0 or 6, sudden loss of blood flow to the leg, or a sudden clot in the leg.
- Severe calcium build-up that rules out treatment through the blood vessels, or untreated major narrowing of the arteries above the leg.
- Stroke within 60 days before the procedure, or unable to take the required blood-thinning drugs.
- Expected to live less than 2 years, or unlikely to finish follow-up.
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Ki vehet részt
- Age >18 years. Willing and able to provide written informed consent. Rutherford Clinical Category 2-5. Angiographically confirmed ≥50% stenosis or occlusion within a previously implanted superficial femoral or proximal popliteal artery stent more than 30 days after implantation
- The target lesion is within the previously stented segment or extends no more than 3 cm proximally or distally beyond the prior stent
- Total target lesion length ≤30 cm. At least one patent below-the-knee runoff vessel. Willing and able to complete follow-up through 24 months. After lesion preparation, both the DCB-first and Eluvia-first strategies remain clinically feasible
Ki nem vehet részt
- Pregnancy or lactation. Rutherford Clinical Category 0 or 6. Target lesion stenosis <50%. Target lesion length >30 cm. Severe calcification precluding endovascular treatment. Acute limb ischemia or acute thrombosis of the target limb. Untreated hemodynamically significant aorto-iliac inflow disease. Cerebrovascular accident within 60 days before the index procedure. Contraindication to required antiplatelet or anticoagulant therapy. Inability or unwillingness to provide informed consent. Life expectancy <2 years or another factor making completion of follow-up unlikely
- Persistent post-preparation anatomy that mandates one treatment strategy and therefore eliminates clinical equipoise
Helyszínek itt: Kína
- Xuanwu Hospital, Capital Medical UniversityBeijing, KínaContact: junjie chenToborzás még nem indult
- Hospital of Chengdu University of Traditional Chinese MedicineChengdu, KínaContact: junjie chenToborzás még nem indult
- Hangzhou First People's HospitalHangzhou, KínaContact: junjie chenToborzás még nem indult
- Qingdao Haici hospital affiliated to Qingdao UniversityQingdao, KínaContact: junjie chenToborzás még nem indult
- Huashan Hospital, Fudan UniversityShanghai, KínaContact: junjie chenToborzás még nem indult
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, KínaContact: junjie chenToborzás még nem indult
- Zhongshan Hospital,Fudan UniversityShanghai, KínaContact: junjie chenToborzás még nem indult
- The Second Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: junjie chenToborzás még nem indult
- Liyuan Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: junjie chenToborzás még nem indult
- Xiamen Cardiovascular Hospital of Xiamen UniversityXiamen, KínaContact: junjie chenToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment. Drug-coated balloons (DCBs) avoid an additional permanent metallic layer, whereas drug-eluting stents provide mechanical scaffolding with local antiproliferative drug delivery. Direct prospective comparative-effectiveness evidence in symptomatic femoropopliteal ISR remains limited.
A teljes eredeti leírásKevesebb
DEFIER is a prospective, multicenter observational comparative-effectiveness cohort study enrolling up to 600 adults with symptomatic Rutherford category 2-5 femoropopliteal ISR. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. After guidewire crossing and lesion preparation, patients for whom both strategies remain clinically feasible enter the primary comparative cohort. The DCB-first strategy uses IN.PACT Admiral or AcoArt Orchid 0.035, with protocol-defined focal bare-metal bailout stenting permitted when clinically required. The Eluvia-first strategy uses the Eluvia drug-eluting vascular stent.
Participants will be followed for 24 months. The primary outcome is the cumulative incidence of first clinically driven target lesion revascularization (CD-TLR) through 24 months. Comparative analyses will use a prespecified target-trial framework and propensity-score overlap weighting, with death and major target-limb amputation treated as competing events.
A vizsgálat 2 csoportja
- DCB-First Strategy Cohort
Participants whose treating physician selects a drug-coated balloon-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The prespecified DCB platforms are IN.PACT Admiral and AcoArt Orchid 0.035. Protocol-defined focal bare-metal bailout stenting is permitted when clinically necessary. Treatment is not assigned by the research protocol.
Kezelés: Drug-Coated Balloon-First Strategy
- Eluvia-First Strategy Cohort
Participants whose treating physician selects an Eluvia-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The strategy uses the Eluvia Drug-Eluting Vascular Stent System. Treatment is not assigned by the research protocol.
Kezelés: Eluvia Drug-Eluting Stent-First Strategy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Title: Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis: A Prospective, Multicenter, Cohort Study (The Defier Study)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 2.